Differentiated Thyroid Cancer (DTC): Clinical Trial Results With LENVIMA® (lenvatinib)Differentiated Thyroid Cancer (DTC): Clinical Trial Results With LENVIMA® (lenvatinib)

Differentiated thyroid cancer and LENVIMA

Getting a diagnosis of differentiated thyroid cancer (DTC) that can no longer be treated with radioactive iodine (RAI) and is progressing can be a shock. If you’ve been diagnosed with DTC, LENVIMA is an FDA-approved prescription treatment that may be an option for you.

LENVIMA was studied in a clinical trial of 392 people with DTC that had progressed and could no longer be treated with RAI.

A clinical study of LENVIMA showed:

59% (154 out of 261 people) of people taking LENVIMA did not have their cancer get worse compared to only 14% (18 out of 131 people) on placebo at the time of follow-up

LENVIMA

154 of 261 people
being treated with LENVIMA did not have their cancer get worse

Placebo

18 of 131 people
being treated with a placebo did not have their cancer get worse

The Median Time People With Differentiated Thyroid Cancer (DTC) Treated With LENVIMA® (lenvatinib) Did Not Have Their Cancer Get Worse Was 18.3 Months Compared to 3.6 Months for Those Taking Placebo
18.3 months

was the median* time people treated with LENVIMA did not have their cancer get worse compared to 3.6 months for those taking placebo. That is approximately 5x longer with LENVIMA than with placebo

*Median: The middle number in a list of numbers arranged from lowest to highest.

65% (169 out of 261 people) treated with LENVIMA had their tumors either partially shrink (partial response) or become undetectable (complete response) compared to 2% (2 out of 131 people) of those treated with placebo

169 of 261 people
had their tumors
shrink

LENVIMA

Partial Response: 63%
(165 of 261 people)

Complete Response: 2%
(4 of 261 people)

2 of 131 people
had their tumors
shrink

Placebo

Partial Response: 2%
(2 of 131 people)

Complete Response: 0%
(0 of 131 people)

How does LENVIMA work?

Understanding what LENVIMA is and how it may work can help set expectations for your treatment journey.